VePesid (etoposide) Disease Interactions
There are 2 disease interactions with VePesid (etoposide):
Antineoplastics (Includes VePesid) ↔ Infections
Severe Potential Hazard, High plausibility
Applies to: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
- "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
- "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
- "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
Etoposide (Includes VePesid) ↔ Myelosuppression
Severe Potential Hazard, High plausibility
Applies to: Bone Marrow Depression/Low Blood Counts, Fever, Bleeding
Etoposide induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3. Clinical monitoring of hematopoetic function is recommended. Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy. At least one determination should be done prior to each dose.
- DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a4491993
- Lokich J Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5- day infusion." Cancer Treat Rep 65 (1981): 887-9
- Niederle N Ostermann J Achterrath W Lenaz L Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991): 59-62
VePesid (etoposide) drug Interactions
There are 339 drug interactions with VePesid (etoposide)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.